BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12(23): 3682-3694 [PMID: 16773685 DOI: 10.3748/wjg.v12.i23.3682] [Cited by in CrossRef: 174] [Cited by in F6Publishing: 165] [Article Influence: 11.6] [Reference Citation Analysis]
Number Citing Articles
1 Ladero JM. Noninvasive evaluation of liver fibrosis in patients with chronic hepatitis C. Hepat Mon 2011;11:698-700. [PMID: 22235211 DOI: 10.5812/kowsar.1735143X.738] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15(18): 2190-2203 [PMID: 19437558 DOI: 10.3748/wjg.15.2190] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
3 Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourlière M, de Muret A, Sturm N, Hunault G, Penaranda G. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem. 2008;41:1368-1376. [PMID: 18655779 DOI: 10.1016/j.clinbiochem.2008.06.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
4 Bonnard P, Elsharkawy A, Zalata K, Delarocque-Astagneau E, Biard L, Le Fouler L, Hassan AB, Abdel-Hamid M, El-Daly M, Gamal ME. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt. J Viral Hepat. 2015;22:245-253. [PMID: 25073725 DOI: 10.1111/jvh.12285] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
5 Gao S, Li XY, Fan YC, Sun FK, Han LY, Li F, Ji XF, Wang K. A noninvasive model to predict liver histology in HBeAg-positive chronic hepatitis B with alanine aminotransferase ≤ 2upper limit of normal. J Gastroenterol Hepatol 2017;32:215-20. [PMID: 27207016 DOI: 10.1111/jgh.13452] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Sebastiani G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat. 2012;19 Suppl 1:18-32. [PMID: 22233410 DOI: 10.1111/j.1365-2893.2011.01518.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
7 El-Shabrawi MH, Isa M. Noninvasive methods to evaluate liver fibrosis in chronic HCV infection. Hepat Mon 2011;11:758-9. [PMID: 22235222 DOI: 10.5812/kowsar.1735143X.711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Cengiz M, Ozenirler S. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:1293-1299. [PMID: 26302023 DOI: 10.1097/meg.0000000000000445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease: ADIPOKINES AND CYTOKINES IN NAFLD. Alimentary Pharmacology & Therapeutics 2008;27:412-21. [DOI: 10.1111/j.1365-2036.2007.03586.x] [Cited by in Crossref: 284] [Cited by in F6Publishing: 276] [Article Influence: 20.3] [Reference Citation Analysis]
10 Correia HS, Domingues AL, Lopes EP, Morais CN, Sarteschi C, Moura IM. [Serum globulin levels and intensity of hepatic fibrosis in patients with mansonic schistosomiasis]. Arq Gastroenterol 2009;46:194-8. [PMID: 19918685 DOI: 10.1590/s0004-28032009000300010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Ibrahim MK, Salama H, Abd El Rahman M, Dawood RM, Bader El Din NG, Salem HF, Abdelrahim ME, Omran D, Omran MH, El-wakeel KH, Abdelhafez TH, Khedr A, El Awady MK. Three Gene Signature for Predicting the Development of Hepatocellular Carcinoma in Chronically Infected Hepatitis C Virus Patients. Journal of Interferon & Cytokine Research 2016;36:698-705. [DOI: 10.1089/jir.2016.0042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
12 Castéra L, Bail BL, Roudot-thoraval F, Bernard P, Foucher J, Merrouche W, Couzigou P, de Lédinghen V. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. Journal of Hepatology 2009;50:59-68. [DOI: 10.1016/j.jhep.2008.08.018] [Cited by in Crossref: 259] [Cited by in F6Publishing: 224] [Article Influence: 21.6] [Reference Citation Analysis]
13 Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights. 2012;7:105-117. [PMID: 22872786 DOI: 10.4137/bmi.s10009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
14 Sebastiani G, Pantopoulos K. Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice. Metallomics 2011;3:971. [DOI: 10.1039/c1mt00082a] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
15 Lieber CS, Weiss DG, Paronetto F. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res. 2008;32:1031-1039. [PMID: 18422837 DOI: 10.1111/j.1530-0277.2008.00664.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
16 Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology. 2009;49:1821-1827. [PMID: 19291784 DOI: 10.1002/hep.22859] [Cited by in Crossref: 126] [Cited by in F6Publishing: 109] [Article Influence: 10.5] [Reference Citation Analysis]
17 Fabris C, Smirne C, Toniutto P, Colletta C, Rapetti R, Minisini R, Falleti E, Leutner M, Pirisi M. Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C. Clin Chem Lab Med 2008;46:253-9. [PMID: 18324909 DOI: 10.1515/CCLM.2008.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
18 Stefano JT, Guedes LV, de Souza AAA, Vanni DS, Alves VAF, Carrilho FJ, Largura A, Arrese M, Oliveira CP. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Ann Hepatol 2021;20:100253. [PMID: 32949785 DOI: 10.1016/j.aohep.2020.08.070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Jeong WK, Lim HK, Lee HK, Jo JM, Kim Y. Principles and clinical application of ultrasound elastography for diffuse liver disease. Ultrasonography 2014;33:149-60. [PMID: 25038804 DOI: 10.14366/usg.14003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 11.4] [Reference Citation Analysis]
20 Calès P, Boursier J, de Lédinghen V, Halfon P, Bacq Y, Leroy V, Dib N, Oberti F, Sawadogo A, Rousselet M, Lunel F. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroentérologie Clinique et Biologique 2008;32:1050-60. [DOI: 10.1016/j.gcb.2008.09.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
21 Palacios Pérez Á, Salmerón Escobar J. Papel de la biopsia hepática en el diagnóstico y el control de la hepatitis C crónica. Gastroenterología y Hepatología 2007;30:402-7. [DOI: 10.1157/13108806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
22 Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912-921. [PMID: 17705266 DOI: 10.1002/hep.21835] [Cited by in Crossref: 251] [Cited by in F6Publishing: 239] [Article Influence: 17.9] [Reference Citation Analysis]
23 Domingues AL, Medeiros TB, Lopes EP. Ultrasound versus biological markers in the evaluation of periportal fibrosis in human Schistosoma mansoni. Mem Inst Oswaldo Cruz 2011;106:802-7. [PMID: 22124551 DOI: 10.1590/s0074-02762011000700004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
24 Razek AA, Abdalla A, Omran E, Fathy A, Zalata K. Diagnosis and quantification of hepatic fibrosis in children with diffusion weighted MR imaging. Eur J Radiol. 2011;78:129-134. [PMID: 19926420 DOI: 10.1016/j.ejrad.2009.10.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
25 Bourlière M, Pénaranda G, Adhoute X, Oules V, Castellani P. Combining non-invasive methods for assessment of liver fibrosis. Gastroentérologie Clinique et Biologique 2008;32:73-9. [DOI: 10.1016/s0399-8320(08)73996-4] [Cited by in Crossref: 9] [Article Influence: 0.7] [Reference Citation Analysis]
26 Liang XE, Zhong C, Huang L, Yang S, Zhu Y, Chen Y, Hou J. Optimization of hepatitis B cirrhosis detection by stepwise application of transient elastography and routine biomarkers: Detection of hepatitis B cirrhosis. Journal of Gastroenterology and Hepatology 2017;32:459-65. [DOI: 10.1111/jgh.13475] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
27 Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M, Morra R, Imbert-Bismut F, Bruckert E, Poynard T. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther. 2007;25:207-218. [PMID: 17229244 DOI: 10.1111/j.1365-2036.2006.03182.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
28 Debernardi-Venon W, Martini S, Biasi F, Vizio B, Termine A, Poli G, Brunello F, Alessandria C, Bonardi R, Saracco G, Rizzetto M, Marzano A. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 2007;46:1026-33. [PMID: 17336417 DOI: 10.1016/j.jhep.2007.01.017] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
29 Shiha G, Seif S, Eldesoky A, Elbasiony M, Soliman R, Metwally A, Zalata K, Mikhail N. A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C. Hepatol Int 2017;11:286-91. [PMID: 28425016 DOI: 10.1007/s12072-017-9796-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
30 Wahl K, Rosenberg W, Vaske B, Manns MP, Schulze-Osthoff K, Bahr MJ, Bantel H. Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. PLoS One 2012;7:e51906. [PMID: 23284811 DOI: 10.1371/journal.pone.0051906] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
31 Cengiz M, Ozenirler S, Elbeg S. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis. J Gastroenterol Hepatol. 2015;30:1190-1196. [PMID: 25684563 DOI: 10.1111/jgh.12924] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
32 Efe C, Cengiz M, Kahramanoğlu-Aksoy E, Yilmaz B, Özşeker B, Beyazt Y, Tanoğlu A, Purnak T, Kav T, Turhan T, Ozenirler S, Ozaslan E, Wahlin S. Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis. Eur J Gastroenterol Hepatol 2015;27:649-54. [PMID: 25860719 DOI: 10.1097/MEG.0000000000000355] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. Proteomics in liver fibrosis is more than meets the eye: . European Journal of Gastroenterology & Hepatology 2008;20:450-64. [DOI: 10.1097/meg.0b013e3282f4de92] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
34 Kula M, Karacavus S, Baskol M, Deniz K, Abdulrezzak U, Tutus A. Hepatobiliary function assessed by 99mTc-mebrofenin cholescintigraphy in the evaluation of fibrosis in chronic hepatitis: histopathological correlation. Nucl Med Commun 2010;31:280-5. [PMID: 20087241 DOI: 10.1097/MNM.0b013e328334bff7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
35 Cequera A, García de León Méndez M. Biomarkers for liver fibrosis: Advances, advantages and disadvantages. Revista de Gastroenterología de México (English Edition) 2014;79:187-99. [DOI: 10.1016/j.rgmxen.2014.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
36 Ragazzo TG, Paranagua-Vezozzo D, Lima FR, de Campos Mazo DF, Pessoa MG, Oliveira CP, Alves VAF, Carrilho FJ. Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. Clinics (Sao Paulo) 2017;72:516-25. [PMID: 29069254 DOI: 10.6061/clinics/2017(09)01] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
37 Attallah AM, Albannan MS, Omran MM, Zayed R, Saif S, Farid A, Hassany M, Yosry A, Omran D. A panel of a mitogenic (PDGF), biochemical (albumin) and demographic (age) parameters for the non-invasive assessment of hepatic fibrosis. Br J Biomed Sci 2019;76:105-10. [PMID: 30924403 DOI: 10.1080/09674845.2019.1600325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Toson el-SA, Shiha GE, El-Mezayen HA, El-Sharkawy AM. Diagnostic performance of T lymphocyte subpopulations in assessment of liver fibrosis stages in hepatitis C virus patients: simple noninvasive score. Eur J Gastroenterol Hepatol 2016;28:931-9. [PMID: 27159125 DOI: 10.1097/MEG.0000000000000656] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
39 Chan HL, de Silva HJ, Leung NW, Lim S, Farrell GC; the Asia–Pacific Working Party on NAFLD. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol 2007;22:801-8. [DOI: 10.1111/j.1440-1746.2007.04977.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
40 Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med. 2008;19:75-82. [PMID: 18249301 DOI: 10.1016/j.ejim.2007.02.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
41 Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V. Assessment of liver fibrosis: noninvasive means. Saudi J Gastroenterol. 2008;14:163-173. [PMID: 19568532 DOI: 10.4103/1319-3767.43273] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
42 Fouad SA, Esmat S, Omran D, Rashid L, Kobaisi MH. Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection. World J Gastroenterol 2012; 18(23): 2988-2994 [PMID: 22736923 DOI: 10.3748/wjg.v18.i23.2988] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
43 Misdraji J. Changing indications for liver biopsy: viral hepatitis. Diagnostic Histopathology 2014;20:119-24. [DOI: 10.1016/j.mpdhp.2014.01.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134:960-974. [PMID: 18395077 DOI: 10.1053/j.gastro.2008.01.034] [Cited by in Crossref: 963] [Cited by in F6Publishing: 890] [Article Influence: 74.1] [Reference Citation Analysis]
45 Colecchia A, Marasco G, Taddia M, Montrone L, Eusebi LH, Mandolesi D, Schiumerini R, Di Biase AR, Festi D. Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients: a review of the literature. European Journal of Gastroenterology & Hepatology 2015;27:992-1001. [DOI: 10.1097/meg.0000000000000393] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
46 Caviglia GP, Ciancio A, Rosso C, Abate ML, Olivero A, Pellicano R, Touscoz GA, Smedile A, Rizzetto M. Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. Annals of Hepatology 2014;13:91-7. [DOI: 10.1016/s1665-2681(19)30909-3] [Cited by in Crossref: 9] [Article Influence: 1.3] [Reference Citation Analysis]
47 Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol. 2011;25:291-303. [PMID: 21497746 DOI: 10.1016/j.bpg.2011.02.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 9.1] [Reference Citation Analysis]
48 Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. [PMID: 21849046 DOI: 10.1186/1471-230x-11-91] [Cited by in Crossref: 181] [Cited by in F6Publishing: 78] [Article Influence: 18.1] [Reference Citation Analysis]
49 de Carli MA, de Carli LA, Correa MB, Junqueira G, Tovo CV, Coral GP. Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2020;32:420-5. [DOI: 10.1097/meg.0000000000001519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
50 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 411] [Cited by in F6Publishing: 368] [Article Influence: 45.7] [Reference Citation Analysis]
51 Pizano-Martínez O, Yañez-Sánchez I, Alatorre-Carranza P, Miranda-Díaz A, Ortiz-Lazareno PC, García-Iglesias T, Daneri-Navarro A, Mercado MVD, Fafutis-Morris M, Delgado-Rizo V. YKL-40 expression in CD14+ liver cells in acute and chronic injury. World J Gastroenterol 2011; 17(33): 3830-3835 [PMID: 21987626 DOI: 10.3748/wjg.v17.i33.3830] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
52 Qi X, An M, Wu T, Jiang D, Peng M, Wang W, Wang J, Zhang C, Chess Study Group OBOT. Transient Elastography for Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis B: A Meta-Analysis. Can J Gastroenterol Hepatol 2018;2018:3406789. [PMID: 29977884 DOI: 10.1155/2018/3406789] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
53 Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014;2014:1-15. [DOI: 10.1155/2014/357287] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
54 Qu Y, Gao C, Zhou K, Zhao Y, Xu M, Lu L. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Annals of Hepatology 2012;11:202-12. [DOI: 10.1016/s1665-2681(19)31025-7] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
55 Norona LM, Nguyen DG, Gerber DA, Presnell SC, LeCluyse EL. Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci 2016;154:354-67. [PMID: 27605418 DOI: 10.1093/toxsci/kfw169] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 17.0] [Reference Citation Analysis]
56 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20(15): 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 58] [Article Influence: 9.3] [Reference Citation Analysis]
57 Bortolotti F, Guido M. Reversal of liver cirrhosis: a desirable clinical outcome and its pathogenic background. J Pediatr Gastroenterol Nutr. 2007;44:401-406. [PMID: 17414134 DOI: 10.1097/mpg.0b013e318032069a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
58 Omran D, Zayed RA, Nabeel MM, Mobarak L, Zakaria Z, Farid A, Hassany M, Saif S, Mostafa M, Saad OK, Yosry A. Evaluating Diagnostic Accuracy of Noninvasive Tests in Assessment of Significant Liver Fibrosis in Chronic Hepatitis C Egyptian Patients. Viral Immunol 2018;31:315-20. [PMID: 29630460 DOI: 10.1089/vim.2017.0134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
60 Toson EA, Shiha GE, El-Mezayen HA, Samir W, El-Khininy MM. Noninvasive estimation of liver fibrosis in biopsy-proven hepatitis C virus-infected patients: angiogenic fibrogenic link. Eur J Gastroenterol Hepatol 2017;29:199-207. [PMID: 27930387 DOI: 10.1097/MEG.0000000000000775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Expert Panel on Liver Stiffness Measurement. Clinical Application of Transient Elastography in the Diagnosis of Liver Fibrosis: an Expert Panel Review and Opinion. J Clin Transl Hepatol 2014;2:110-6. [PMID: 26357622 DOI: 10.14218/JCTH.2014.00008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
62 Cholongitas E, Burroughs AK, Dhillon AP. Liver Biopsy. In: Mcdonald JW, Burroughs AK, Feagan BG, Fennerty MB, editors. Evidence‐Based Gastroenterology and Hepatology. Wiley; 2010. pp. 762-70. [DOI: 10.1002/9781444314403.ch46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Toson EA, Shiha GE, Abdelgaleel AE. Fibrogenic/Angiogenic Linker for Non-Invasive Assessment of Hepatic Fibrosis Staging in Chronic Hepatitis C Among Egyptian Patients. Ann Hepatol 2017;16:862-73. [PMID: 29055924 DOI: 10.5604/01.3001.0010.5276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Dawood RM, El-Meguid MA, Ibrahim MK, Bader El Din NG, Barakat A, El-Wakeel K, Alla MDAA, Wu GY, El Awady MK. Dysregulation of fibrosis related genes in HCV induced liver disease. Gene 2018;664:58-69. [PMID: 29684485 DOI: 10.1016/j.gene.2018.04.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
65 Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P, Carrat F. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008;54:1372-8. [PMID: 18539647 DOI: 10.1373/clinchem.2007.097923] [Cited by in Crossref: 97] [Cited by in F6Publishing: 93] [Article Influence: 7.5] [Reference Citation Analysis]
66 Mak KM, Png CYM, Lee DJ. Type V Collagen in Health, Disease, and Fibrosis: TYPE V COLLAGEN. Anat Rec 2016;299:613-29. [DOI: 10.1002/ar.23330] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 12.8] [Reference Citation Analysis]
67 Reshetnyak VI. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis. World J Gastroenterol 2015; 21(25): 7683-7708 [PMID: 26167070 DOI: 10.3748/wjg.v21.i25.7683] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
68 Liu HB, Zhou JP, Zhang Y, Lv XH, Wang W. Prediction on liver fibrosis using different APRI thresholds when patient age is a categorical marker in patients with chronic hepatitis B. Clin Chim Acta. 2011;412:33-37. [PMID: 20828546 DOI: 10.1016/j.cca.2010.08.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
69 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
70 Valva P, Casciato P, Lezama C, Galoppo M, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV. Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children. PLoS One. 2013;8:e53519. [PMID: 23326448 DOI: 10.1371/journal.pone.0053519] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
71 Calès P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, Foucher J, Bourlière M, de Muret A, Sturm N. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int. 2008;28:1352-1362. [PMID: 18492022 DOI: 10.1111/j.1478-3231.2008.01789.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
72 Poynard T, Halfon P, Castera L, Charlotte F, Le Bail B, Munteanu M, Messous D, Ratziu V, Benhamou Y, Bourlière M. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther. 2007;25:733-739. [PMID: 17311607 DOI: 10.1111/j.1365-2036.2007.03252.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 4.6] [Reference Citation Analysis]
73 Neuman MG, Schmilovitz-Weiss H, Hilzenrat N, Bourliere M, Marcellin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA. Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. Int J Hepatol. 2012;2012:231210. [PMID: 22530132 DOI: 10.1155/2012/231210] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
74 Alempijevic T, Krstic M, Jesic R, Jovanovic I, Milutinovic AS, Kovacevic N, Krstic S, Popovic D. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World J Gastroenterol 2009; 15(5): 591-594 [PMID: 19195061 DOI: 10.3748/wjg.15.591] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
75 Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med. 2014;14:121-131. [PMID: 23292294 DOI: 10.1007/s10238-012-0227-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
76 Almpanis Z, Demonakou M, Tiniakos D. Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol 2016;29:445-53. [PMID: 27708509 DOI: 10.20524/aog.2016.0046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
77 Cequera A, García de León Méndez MC. [Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Rev Gastroenterol Mex 2014;79:187-99. [PMID: 24954541 DOI: 10.1016/j.rgmx.2014.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
78 Boursier J, Bacq Y, Halfon P, Leroy V, de Ledinghen V, de Muret A, Bourlière M, Sturm N, Foucher J, Oberti F, Rousselet MC, Calès P. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C: . European Journal of Gastroenterology & Hepatology 2009;21:28-38. [DOI: 10.1097/meg.0b013e32830cebd7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
79 Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, Lebray P, Thabut D, Morra R, Messous D, Charlotte F, Imbert-Bismut F, Bonnefont-Rousselot D, Moussalli J, Ratziu V, Poynard T. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS One 2008;3:e2573. [PMID: 18596917 DOI: 10.1371/journal.pone.0002573] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
80 Kayadibi H, Yasar B, Ozkara S, Serdar MA, Kurdas OO, Gonen C. The diagnostic accuracy of the Forns index, platelet count and AST to Platelet Ratio Index derived fibrosis index for the prediction of Hepatitis C virus-related significant liver fibrosis and cirrhosis. Scand J Clin Lab Invest. 2014;74:240-247. [PMID: 24460024 DOI: 10.3109/00365513.2013.879392] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
81 Hsu CS, Kao JH. Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan. J Formos Med Assoc. 2012;111:527-535. [PMID: 23089687 DOI: 10.1016/j.jfma.2012.07.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
82 Poynard T, Ingiliz P, Elkrief L, Munteanu M, Lebray P, Morra R, Messous D, Bismut FI, Roulot D, Benhamou Y. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One. 2008;3:e3857. [PMID: 19052646 DOI: 10.1371/journal.pone.0003857] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
83 Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, Manns MP, Schulze-osthoff K, Bantel H. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012;55:455-64. [DOI: 10.1002/hep.24734] [Cited by in Crossref: 125] [Cited by in F6Publishing: 112] [Article Influence: 12.5] [Reference Citation Analysis]
84 Abdollahi M, Pouri A, Ghojazadeh M, Estakhri R, Somi M. Non-invasive serum fibrosis markers: A study in chronic hepatitis. Bioimpacts. 2015;5:17-23. [PMID: 25901293 DOI: 10.15171/bi.2015.05] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
85 Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol 2011; 3(8): 219-227 [PMID: 21954411 DOI: 10.4254/wjh.v3.i8.219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
86 Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. Clin Chem Lab Med. 2011;49:13-32. [PMID: 20961196 DOI: 10.1515/cclm.2011.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
87 Van Leeuwen DJ, Balabaud C, Crawford JM, Bioulac–sage P, Dhillon AP. A Clinical and Histopathologic Perspective on Evolving Noninvasive and Invasive Alternatives for Liver Biopsy. Clinical Gastroenterology and Hepatology 2008;6:491-6. [DOI: 10.1016/j.cgh.2008.02.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
88 Salkic NN, Cickusic E, Jovanovic P, Denjagic MB, Iljazovic-Topcic S, Bevanda M, Ahmetagic S. Online combination algorithm for non-invasive assessment of chronic hepatitis B related liver fibrosis and cirrhosis in resource-limited settings. Eur J Intern Med. 2015;26:628-634. [PMID: 26194460 DOI: 10.1016/j.ejim.2015.07.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
89 Elhosary YA, Saleh SM, Ezzat WM, Clevert DA. Diagnostic Accuracy of Acoustic Radiation Force Impulse (ARFI) in Diagnosis of Liver Fibrosis among Egyptian Patients with Chronic HCV Infection. Open Access Maced J Med Sci 2016;4:374-80. [PMID: 27703558 DOI: 10.3889/oamjms.2016.064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
90 Calès P, Veillon P, Konaté A, Mathieu E, Ternisien C, Chevailler A, Godon A, Gallois Y, Joubaud F, Hubert-Fouchard I. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem. 2008;41:10-18. [PMID: 17988658 DOI: 10.1016/j.clinbiochem.2007.08.009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
91 Burroughs AK, Cholongitas E. Non-invasive tests for liver fibrosis: encouraging or discouraging results? J Hepatol. 2007;46:751-755. [PMID: 17383047 DOI: 10.1016/j.jhep.2007.02.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
92 Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2013;7:356-68. [PMID: 26201770 DOI: 10.1007/s12072-013-9439-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
93 Mak KM, Mei R. Basement Membrane Type IV Collagen and Laminin: An Overview of Their Biology and Value as Fibrosis Biomarkers of Liver Disease. Anat Rec (Hoboken). 2017;300:1371-1390. [PMID: 28187500 DOI: 10.1002/ar.23567] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 19.8] [Reference Citation Analysis]
94 Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009;16:300-314. [PMID: 19254351 DOI: 10.1111/j.1365-2893.2009.01087.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 9.4] [Reference Citation Analysis]
95 Shin SK, Kim JH, Park H, Kwon OS, Lee HJ, Yeon JE, Byun KS, Suh SJ, Yim HJ, Kim YS. Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment. J Gastroenterol Hepatol. 2015;30:1775-1781. [PMID: 26095700 DOI: 10.1111/jgh.13020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
96 Sethi S, Simonetto DA, Abdelmoneim SS, Campion MB, Kaloiani I, Clayton AC, Kremers WK, Halling KC, Kamath PS, Talwalkar J, Shah VH. Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis. J Clin Exp Hepatol 2012;2:19-26. [PMID: 25755402 DOI: 10.1016/S0973-6883(12)60078-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
97 Plebani M, Basso D. Non-invasive assessment of chronic liver and gastric diseases. Clin Chim Acta. 2007;381:39-49. [PMID: 17374528 DOI: 10.1016/j.cca.2007.02.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
98 Mangus RS, O'Connor MG, Tector AJ, Lim JD, Vianna RM. Use of the aspartate aminotransferase to platelet ratio index to follow liver fibrosis progression in infants with short gut. J Pediatr Surg 2010;45:1266-73. [PMID: 20620330 DOI: 10.1016/j.jpedsurg.2010.02.098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
99 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
100 Owojuyigbe OS, Larbie C, Firempong CK, Komlaga G, Emikpe BO, Oyagbemi AA. Hura crepitans stem bark extract: A potential remedy to sub-acute liver damage. J Ethnopharmacol 2021;284:114768. [PMID: 34688802 DOI: 10.1016/j.jep.2021.114768] [Reference Citation Analysis]
101 Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C: Combination algorithms for liver fibrosis in HCV. Alimentary Pharmacology & Therapeutics 2012;35:92-104. [DOI: 10.1111/j.1365-2036.2011.04897.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
102 Sebastiani G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat. 2008;15:212-218. [PMID: 18179453 DOI: 10.1111/j.1365-2893.2007.00932.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
103 Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications. Hepatology 2008;47:332-42. [DOI: 10.1002/hep.21972] [Cited by in Crossref: 232] [Cited by in F6Publishing: 211] [Article Influence: 16.6] [Reference Citation Analysis]
104 Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T. FibroMAX: towards a new universal biomarker of liver disease? Expert Rev Mol Diagn 2007;7:481-90. [PMID: 17892356 DOI: 10.1586/14737159.7.5.481] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
105 Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V. Biomarkers of liver fibrosis. Adv Clin Chem. 2008;46:131-160. [PMID: 19004189 DOI: 10.1016/s0065-2423(08)00404-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
106 Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases: Liver fibrosis biomarkers, aetiology and fibrosis stages. Alimentary Pharmacology & Therapeutics 2011;34:1202-16. [DOI: 10.1111/j.1365-2036.2011.04861.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
107 Voumvouraki A, Koulentaki M, Notas G, Sfakianaki O, Kouroumalis E. Serum surrogate markers of liver fibrosis in primary biliary cirrhosis. Eur J Intern Med. 2011;22:77-83. [PMID: 21238899 DOI: 10.1016/j.ejim.2010.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
108 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
109 Salkic NN, Jovanovic P, Hauser G, Brcic M. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol 2014;109:796-809. [PMID: 24535095 DOI: 10.1038/ajg.2014.21] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
110 Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835-847. [PMID: 18334275 DOI: 10.1016/j.jhep.2008.02.008] [Cited by in Crossref: 873] [Cited by in F6Publishing: 807] [Article Influence: 67.2] [Reference Citation Analysis]
111 Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Moussalli J, Lebray P, Thabut D, Ratziu V. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. Clin Res Hepatol Gastroenterol 2011;35:720-30. [PMID: 21852224 DOI: 10.1016/j.clinre.2011.07.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
112 Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy. Am J Gastroenterology 2007;102:2589-600. [DOI: 10.1111/j.1572-0241.2007.01466.x] [Cited by in Crossref: 233] [Cited by in F6Publishing: 220] [Article Influence: 16.6] [Reference Citation Analysis]
113 Peng SS, Jeng YM, Hsu WM, Yang JC, Ho MC. Hepatic ADC map as an adjunct to conventional abdominal MRI to evaluate hepatic fibrotic and clinical cirrhotic severity in biliary atresia patients. Eur Radiol 2015;25:2992-3002. [PMID: 25921590 DOI: 10.1007/s00330-015-3716-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
114 Viana MSVB, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Annals of Hepatology 2009;8:26-31. [DOI: 10.1016/s1665-2681(19)31807-1] [Cited by in Crossref: 35] [Article Influence: 2.9] [Reference Citation Analysis]
115 Bourlière M, Kahloun A, Gascou-Tessonnier G. Analogs and fibrosis regression in hepatitis B. Gastroenterol Clin Biol 2009;33:923-9. [PMID: 19640665 DOI: 10.1016/j.gcb.2009.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
116 Papastamataki M, Delaporta P, Premetis E, Kattamis A, Ladis V, Papassotiriou I. Evaluation of liver fibrosis in patients with thalassemia: The important role of hyaluronic acid. Blood Cells, Molecules, and Diseases 2010;45:215-8. [DOI: 10.1016/j.bcmd.2010.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
117 Wan M, Xu H, Li D, Wang L, Li X. Accuracy of gamma-glutamyl transpeptidase-to-platelet ratio (GPR), red cell distribution width (RDW), aspartate aminotransferase-to-platelet ratio index (APRI), and the fibrosis-4 index (FIB4) compared with liver biopsy in patients with drug-induced liver injury (DILI). Medicine (Baltimore) 2021;100:e24723. [PMID: 33578617 DOI: 10.1097/MD.0000000000024723] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One. 2011;6:e23218. [PMID: 21858035 DOI: 10.1371/journal.pone.0023218] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
119 Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol 2016; 22(16): 4079-4090 [PMID: 27122660 DOI: 10.3748/wjg.v22.i16.4079] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 51] [Article Influence: 11.8] [Reference Citation Analysis]
120 Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, Rousselet MC, Hubert I, Laafi J. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009;50:165-173. [PMID: 18977552 DOI: 10.1016/j.jhep.2008.07.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 139] [Article Influence: 13.1] [Reference Citation Analysis]
121 Ingiliz P, Chhay KP, Munteanu M, Lebray P, Ngo Y, Roulot D, Benhamou Y, Thabut D, Ratziu V, Poynard T. Applicability and variability of liver stiffness measurements according to probe position. World J Gastroenterol 2009; 15(27): 3398-3404 [PMID: 19610141 DOI: 10.3748/wjg.15.3398] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
122 Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014; 20(32): 11033-11053 [PMID: 25170193 DOI: 10.3748/wjg.v20.i32.11033] [Cited by in CrossRef: 117] [Cited by in F6Publishing: 97] [Article Influence: 16.7] [Reference Citation Analysis]
123 Pan AN, Xu WW, Luo YL, Yu HH, Hu YB, Sun QF, Ding JG, Wu YH. A novel system for predicting liver histopathology in patients with chronic hepatitis B. Medicine (Baltimore) 2017;96:e6465. [PMID: 28383410 DOI: 10.1097/MD.0000000000006465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
124 Messner CJ, Schmidt S, Özkul D, Gaiser C, Terracciano L, Krähenbühl S, Suter-Dick L. Identification of miR-199a-5p, miR-214-3p and miR-99b-5p as Fibrosis-Specific Extracellular Biomarkers and Promoters of HSC Activation. Int J Mol Sci 2021;22:9799. [PMID: 34575957 DOI: 10.3390/ijms22189799] [Reference Citation Analysis]
125 Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci. 2009;46:83-106. [PMID: 19255916 DOI: 10.1080/10408360802610878] [Cited by in Crossref: 164] [Cited by in F6Publishing: 148] [Article Influence: 13.7] [Reference Citation Analysis]
126 Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010;10:103. [PMID: 20828377 DOI: 10.1186/1471-230x-10-103] [Cited by in Crossref: 83] [Cited by in F6Publishing: 43] [Article Influence: 7.5] [Reference Citation Analysis]
127 Castera L. Assessing liver fibrosis. Expert Rev Gastroenterol Hepatol. 2008;2:541-552. [PMID: 19072402 DOI: 10.1586/17474124.2.4.541] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
128 Elesawy BH, Abd El Hafez A, Dorgham LS, El-Askary A. Limited reliability of five non-invasive biomarkers in predicting hepatic fibrosis in chronic HCV mono-infected patients opposed to METAVIR scoring. Pathol Res Pract. 2014;210:922-928. [PMID: 25123964 DOI: 10.1016/j.prp.2014.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
129 Jafari R, Hectors SJ, Koehne de González AK, Spincemaille P, Prince MR, Brittenham GM, Wang Y. Integrated quantitative susceptibility and R2 * mapping for evaluation of liver fibrosis: An ex vivo feasibility study. NMR Biomed 2021;34:e4412. [PMID: 32959425 DOI: 10.1002/nbm.4412] [Reference Citation Analysis]
130 Cai J, Osikowicz M, Sebastiani G. Clinical significance of elevated liver transaminases in HIV-infected patients. AIDS 2019;33:1267-82. [PMID: 31008799 DOI: 10.1097/QAD.0000000000002233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
131 Marsillach J, Parra S, Ferré N, Coll B, Alonso-villaverde C, Joven J, Camps J. Paraoxonase-1 in Chronic Liver Diseases, Neurological Diseases and HIV Infection. In: Mackness B, Mackness M, Aviram M, Paragh G, editors. The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism. Dordrecht: Springer Netherlands; 2008. pp. 187-98. [DOI: 10.1007/978-1-4020-6561-3_12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
132 Valva P, Ríos DA, De Matteo E, Preciado MV. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol 2016; 22(4): 1367-1381 [PMID: 26819506 DOI: 10.3748/wjg.v22.i4.1367] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
133 Nieminen U, Arkkila PE, Kärkkäinen P, Färkkilä MA. Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. Liver Int. 2009;29:153-158. [PMID: 18482270 DOI: 10.1111/j.1478-3231.2008.01779.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
134 Maieron A, Salzl P, Peck-Radosavljevic M, Trauner M, Hametner S, Schöfl R, Ferenci P, Ferlitsch M. Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014;39:331-338. [PMID: 24308724 DOI: 10.1111/apt.12564] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
135 El-Mezayen HA, Habib S, Marzok HF, Saad MH. Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study. Eur J Gastroenterol Hepatol. 2015;27:378-385. [PMID: 25874509 DOI: 10.1097/meg.0000000000000298] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
136 Ahmed Hassan E, Sharaf El-Din Abd El-Rehim A, Ahmed Sayed ZE, Farah Mohamed Kholef E, Sabry A, Abd El-Rehim Abo Elhagag N. VAP score as a novel non-invasive liver fibrosis model in patients with chronic hepatitis C. Hepatol Res 2017;47:1408-16. [PMID: 28247581 DOI: 10.1111/hepr.12884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
137 Trifan A, Stanciu C. Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol 2012; 18(39): 5514-5520 [PMID: 23112543 DOI: 10.3748/wjg.v18.i39.5514] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
138 Poynard T. Faut-il encore faire des biopsies du foie ? La Revue de Médecine Interne 2007;28:67-70. [DOI: 10.1016/j.revmed.2006.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
139 Levelt E, Pavlides M, Banerjee R, Mahmod M, Kelly C, Sellwood J, Ariga R, Thomas S, Francis J, Rodgers C, Clarke W, Sabharwal N, Antoniades C, Schneider J, Robson M, Clarke K, Karamitsos T, Rider O, Neubauer S. Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes. J Am Coll Cardiol 2016;68:53-63. [PMID: 27364051 DOI: 10.1016/j.jacc.2016.03.597] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 22.0] [Reference Citation Analysis]
140 Attallah AM, Omran MM, Farid K, El-Bendary M, Emran TM, Albannan MS, El-Dosoky I. Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients. Clin Chim Acta. 2012;413:1725-1730. [PMID: 22759976 DOI: 10.1016/j.cca.2012.06.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
141 Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat. 2009;16:203-213. [PMID: 19175871 DOI: 10.1111/j.1365-2893.2008.01065.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
142 Stankovic Z. Four-dimensional flow magnetic resonance imaging in cirrhosis. World J Gastroenterol 2016; 22(1): 89-102 [PMID: 26755862 DOI: 10.3748/wjg.v22.i1.89] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
143 Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med. 2007;11:1031-1051. [PMID: 17979881 DOI: 10.1111/j.1582-4934.2007.00092.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 5.3] [Reference Citation Analysis]
144 Raoufy MR, Vahdani P, Alavian SM, Fekri S, Eftekhari P, Gharibzadeh S. A Novel Method for Diagnosing Cirrhosis in Patients with Chronic Hepatitis B: Artificial Neural Network Approach. J Med Syst 2011;35:121-6. [DOI: 10.1007/s10916-009-9348-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
145 Oancea CN, Butaru AE, Streba CT, Pirici D, Rogoveanu I, Diculescu MM, Gheonea DI. Global hepatitis C elimination: history, evolution, revolutionary changes and barriers to overcome. Rom J Morphol Embryol 2020;61:643-53. [PMID: 33817705 DOI: 10.47162/RJME.61.3.02] [Reference Citation Analysis]
146 Cengiz M, Ozenirler S, Kocabiyik M. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis: . European Journal of Gastroenterology & Hepatology 2016;28:57-63. [DOI: 10.1097/meg.0000000000000502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
147 Castéra L, Sebastiani G, Le Bail B, de Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. Journal of Hepatology 2010;52:191-8. [DOI: 10.1016/j.jhep.2009.11.008] [Cited by in Crossref: 139] [Cited by in F6Publishing: 122] [Article Influence: 12.6] [Reference Citation Analysis]
148 Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, Tran A, Botta D, Renou C, Bréchot MC. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:395-402. [PMID: 17156890 DOI: 10.1016/j.jhep.2006.09.020] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 6.3] [Reference Citation Analysis]
149 Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007; 13(4): 525-531 [PMID: 17278217 DOI: 10.3748/wjg.v13.i4.525] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 88] [Article Influence: 7.0] [Reference Citation Analysis]
150 Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, Pérez-López R, Castellano-Megias VM, Nevado-Santos M, Alcón JC. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology. 2008;47:810-816. [PMID: 18098299 DOI: 10.1002/hep.22112] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
151 Biasiolo A, Chemello L, Quarta S, Cavalletto L, Bortolotti F, Caberlotto C, Beneduce L, Bernardinello E, Tono N, Fassina G, Gatta A, Pontisso P. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. J Viral Hepat 2008;15:246-9. [DOI: 10.1111/j.1365-2893.2007.00935.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
152 Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007;7:40. [PMID: 17937811 DOI: 10.1186/1471-230x-7-40] [Cited by in Crossref: 205] [Cited by in F6Publishing: 76] [Article Influence: 14.6] [Reference Citation Analysis]
153 Attallah AM, El-Far M, Omran MM, Farid K, Albannan MS, El-Dosoky I. Noninvasive diagnosis of liver fibrosis and cirrhosis in chronic hepatitis C patients. J Clin Lab Anal 2013;27:121-9. [PMID: 23460258 DOI: 10.1002/jcla.21572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
154 Chen Y, Liang X. Non-invasive assessment of liver fibrosis: reduce or substitute the need for liver biopsy? Liver Int 2015;35:2483-2483. [DOI: 10.1111/liv.12824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
155 Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011;5:625-634. [PMID: 21484142 DOI: 10.1007/s12072-010-9240-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
156 Castera L, Denis J, Babany G, Roudot-thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: Time for new guidelines? Journal of Hepatology 2007;46:528-9. [DOI: 10.1016/j.jhep.2006.12.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.5] [Reference Citation Analysis]
157 Monti L, Salsano M, Candusso M, Avolio AW, Soglia G, Marino M, Francalanci P, Spada M, Toma P. Diagnosis of Acute Rejection of Liver Grafts in Young Children Using Acoustic Radiation Force Impulse Imaging. AJR Am J Roentgenol 2020;215:1229-37. [PMID: 32877250 DOI: 10.2214/AJR.19.22057] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Poynard T, Muntenau M, Morra R, Ngo Y, Imbert-Bismut F, Thabut D, Messous D, Massard J, Lebray P, Moussalli J. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Gastroenterol Clin Biol. 2008;32:8-21. [PMID: 18973843 DOI: 10.1016/s0399-8320(08)73990-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
159 Brissot P, Troadec MB, Bardou-Jacquet E, Le Lan C, Jouanolle AM, Deugnier Y, Loréal O. Current approach to hemochromatosis. Blood Rev 2008;22:195-210. [PMID: 18430498 DOI: 10.1016/j.blre.2008.03.001] [Cited by in Crossref: 92] [Cited by in F6Publishing: 78] [Article Influence: 7.1] [Reference Citation Analysis]
160 Tomer S, Arora SK. A juggernaut of innate & adaptive immune cells in chronic hepatitis C. Indian J Med Res 2020;151:279-86. [PMID: 32461391 DOI: 10.4103/ijmr.IJMR_1387_17] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Orasan OH, Iancu M, Sava M, Saplontai-Pop A, Cozma A, Sarlea ST, Lungoci C, Ungureanu MI, Negrean V, Sampelean D, Dumitrascu DL. Non-invasive assessment of liver fibrosis in chronic viral hepatitis. Eur J Clin Invest 2015;45:1243-51. [PMID: 26426402 DOI: 10.1111/eci.12543] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
162 Mendes LC, Ferreira PA, Miotto N, Zanaga L, Gonçales E, Lazarini MS, Gonçales FL Júnior, Stucchi RS, Vigani AG. Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C. Braz J Med Biol Res 2016;49:e5432. [PMID: 27533769 DOI: 10.1590/1414-431X20165432] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
163 Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V. Assessment of liver fibrosis: noninvasive means. Saudi J Gastroenterol. 2008;14:163-173. [PMID: 19568532 DOI: 10.4103/1319-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
164 Uslusoy HS, Nak SG, Gülten M, Bıyıklı Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol 2009; 15(15): 1863-1868 [PMID: 19370784 DOI: 10.3748/wjg.15.1863] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
165 Cholongitas E, Tsochatzis E, Goulis J, Burroughs AK. Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review. Transpl Int. 2010;23:861-870. [PMID: 20704691 DOI: 10.1111/j.1432-2277.2010.01142.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]